Premium
Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double‐blind placebo‐controlled trial
Author(s) -
Feldman S.R.,
Gordon K.B.,
Bala M.,
Evans R.,
Li S.,
Dooley L.T.,
Guzzo C.,
Patel K.,
Menter A.,
Gottlieb A.B.
Publication year - 2005
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.2005.06510.x
Subject(s) - psoriasis , infliximab , medicine , placebo , quality of life (healthcare) , double blind , dermatology , physical therapy , alternative medicine , tumor necrosis factor alpha , pathology , nursing
Summary Background Psoriasis is a chronic disease that significantly diminishes the health‐related quality of life (HRQOL). Infliximab is a chimeric, tumour necrosis factor α monoclonal antibody that has been shown to improve the signs and symptoms of plaque psoriasis. Objectives The objective of this study was to evaluate the effect of infliximab induction therapy on the HRQOL of patients with severe plaque psoriasis. Methods In this double‐blind, placebo‐controlled trial, 249 patients were randomly assigned to receive intravenous infusions of 3 or 5 mg kg −1 of infliximab or placebo and were treated at weeks 0, 2 and 6. Patients completed the Dermatology Life Quality Index (DLQI) at baseline and week 10. Results Infliximab induction therapy resulted in a substantial improvement in HRQOL. At week 10, patients in the infliximab 3‐ and 5‐mg kg −1 groups showed a median percentage improvement in DLQI scores of 84·0% and 91·0%, respectively, compared with 0% in the placebo group ( P < 0·001). The median decrease from baseline in DLQI score at week 10 was 8·0 and 10·0 for the 3 and 5 mg kg −1 infliximab groups, respectively, compared with 0 in the placebo group ( P < 0·001). Thirty‐three per cent and 40% of patients in the 3 and 5 mg kg −1 infliximab groups, respectively, had a DLQI score of 0 at week 10, compared with 2% in the placebo group ( P < 0·001). There was a strong correlation between the percentage change from baseline at week 10 in Psoriasis Area and Severity Index (PASI) scores and the percentage change in DLQI scores during the same period (Spearman's correlation, 0·61, P < 0·001). When the infliximab and placebo treatment groups were combined, patients with at least 75% improvement in PASI scores between baseline and week 10 had a greater mean improvement in DLQI scores (81%) than those with 50–75% improvement in PASI during the same period (60%). Conclusions Infliximab induction therapy resulted in significant improvement in HRQOL in patients with severe psoriasis.